Broad access to home testing can expand the spectrum of ways telehealth can be used, and likewise, leveraging telehealth to supervise sample collection at home and interpretation of results could expand the potential of tests that can be effectively done outside of a clinic or healthcare facility. But lab test availability in the home has been limited and lab tests are not generally available for telehealth encounters. While the COVID-19 pandemic has greatly accelerated the market availability of over-the-counter home sample collection and home testing solutions, either with or without a prescription, adoption has been relatively modest.

The Home Testing SIG brings together medical, scientific, technology solution, laboratory and regulatory experts to address barriers to adoption and to accelerate use of home testing as a part of virtual care.

Some of the questions we’ll be addressing: What are the barriers? Does a lack of a common industry language around home testing slow down adoption? Do the lack of specific performance requirements contribute to a lack of clarity in regulation and limited reimbursement? What can industry do to help accelerate home testing adoption by better connection to telehealth solutions?

All players with a role in the remote testing ecosystem are encouraged to join the ATA and its new Home Testing SIG to define an industry vision, identify the barriers and collaborate in catalyzing industry action to accelerate adoption of home testing with and for telehealth.

Making the Case for Non-Discriminatory Regulation and Reimbursement for Home Testing

Testing at Home Terms Guide